Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive

Michelle Martinot-Peignoux1, Roberto Carvalho-Filho, Martine Lapalus

  • 1Centre de Recherche Biomédicale Bichat-Beaujon (CRB3), INSERM U-773 and Service d'Hépatologie Hôpital Beaujon APHP, Université Paris-Diderot, 92110 Clichy, France. michelle.martinot@inserm.fr

Journal of Hepatology
|February 2, 2013
PubMed

Insights

Low serum HBsAg levels are linked to severe liver fibrosis in chronic hepatitis B (CHB) patients. A specific HBsAg cutoff may predict fibrosis in certain HBV genotypes.

Area of Science:

  • Hepatology
  • Virology
  • Biochemistry

Background:

  • Chronic hepatitis B (CHB) is a significant global health concern.
  • Understanding the relationship between viral markers and liver disease severity is crucial for patient management.
  • Limited data exists on serum HBsAg and HBV DNA levels in relation to liver disease severity in treatment-naïve CHB patients.

Purpose of the Study:

  • To investigate the association between serum HBsAg and HBV DNA levels and liver disease severity in a large cohort of treatment-naïve CHB patients.
  • To explore the predictive value of serum HBsAg levels for fibrosis severity.

Main Methods:

  • Cross-sectional study of 406 treatment-naïve CHB patients.
  • Simultaneous collection of serum samples and liver biopsies.
  • Quantification of serum HBsAg, HBV DNA, and HBV genotype; histological scoring using the METAVIR system.

Main Results:

  • Strong correlation between serum HBsAg and HBV DNA levels in HBeAg(+) patients (r=0.44).
  • Significant association between serum HBsAg levels and fibrosis severity (r=0.43).
  • HBeAg(+) patients with moderate to severe fibrosis showed lower serum HBsAg and HBV DNA levels.
  • A serum HBsAg cut-off of 3.85 logIU/ml demonstrated high predictive value for fibrosis in HBV genotypes B or C.

Conclusions:

  • Low serum HBsAg levels are associated with moderate to severe liver fibrosis in HBeAg(+) CHB patients.
  • A serum HBsAg cut-off can predict fibrosis severity in CHB patients with HBV genotypes B or C.
  • These findings offer insights into non-invasive fibrosis assessment in CHB management.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...